Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?The Motley Fool • 02/17/24
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic FibrosisBusiness Wire • 02/15/24
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company UpdatesGlobeNewsWire • 02/14/24
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of MedicineGlobeNewsWire • 01/31/24
History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does.The Motley Fool • 01/30/24
Down -19.06% in 4 Weeks, Here's Why Intellia Therapeutics, Inc. (NTLA) Looks Ripe for a TurnaroundZacks Investment Research • 01/29/24
2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall StreetThe Motley Fool • 01/27/24
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosaGlobeNewsWire • 01/24/24
Intellia Therapeutics Layoffs 2024: What to Know About the Latest NTLA Job CutsInvestorPlace • 01/05/24
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key MilestonesGlobeNewsWire • 01/04/24